scholarly journals Adherence to Therapeutic Recommendations in Patients Suffering from Multiple Sclerosis

2020 ◽  
Vol 9 (3) ◽  
pp. 103-107
Author(s):  
Joanna Olkiewicz ◽  
◽  
Robert Bonek ◽  
Karolina Filipska ◽  
Robert Ślusarz ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Central Nervous System ◽  
Demyelinating Disease ◽  
Medical Data ◽  
Study Group ◽  
Fatigue Syndrome ◽  
Adherence Scale ◽  
The Central Nervous System ◽  
Therapeutic Recommendations ◽  
High Level

Introduction. Multiple sclerosis is a chronic, inflammatory, immune demyelinating disease of the central nervous system. The effectiveness of MS treatment depends primarily on the effectiveness of drugs and the patient’s compliance with the principles of therapy. Aim. The main aim of the study was to assess the level of adherence to therapeutic recommendations in patients with multiple sclerosis. Material and Methods. The research was carried out at the Department of Neurology and Clinical Neuroimmunology of the Regional Specialist Hospital in Grudziądz. On average 165 patients suffering from multiple sclerosis were qualified for the study. The study was conducted using the method of diagnostic survey. The variables were measured using the proprietary questionnaire containing sociodemographic and medical data and the standardized adherence scale in chronic diseases (ACDS). Results. The analysis of own research showed that patients with high-level multiple sclerosis adhere to the therapeutic recommendations (p = 0.001). The study group reported the fatigue syndrome at all ACDS levels (p = 0.002). There was no relationship between the occurrence of adverse effects of pharmacotherapy and the level of compliance with therapeutic recommendations (p > 0.05). Conclusions. It was found that the level of adherence to therapeutic recommendations in patients suffering from multiple sclerosis in the study group remained at a high level. (JNNN 2020;9(3):103–107) Key Words: adherence, multiple sclerosis, therapeutic recommendations

Multiple Sclerosis

2018 ◽  
pp. 209-216
Author(s):  
Samuel W. Samuel ◽  
Jianguo Cheng
Keyword(s):  
Multiple Sclerosis ◽  
Central Nervous System ◽  
Neuropathic Pain ◽  
Demyelinating Disease ◽  
Spontaneous Pain ◽  
Disease Course ◽  
The Central Nervous System ◽  
Disease Modifying ◽  
Multiple Treatments ◽  
Surgical Treatments

Multiple sclerosis (MS) is a chronic autoimmune demyelinating disease of the central nervous system (CNS). The diagnosis is based on evidence of at lease two different lesions in the CNS, at least two different episodes in the disease course, and chronic inflammation of the CNS as determined by analysis of the cerebrospinal fluid. Central neuropathic pain is the most common form of pain in patients with MS, with an estimated prevalence of about 50%. Along with the classical neuropathic pain features, such as spontaneous pain (dysesthesia and burning) and evoked pain (allodynia and hyperalgesia), patients with MS may also suffer from intermittent neuropathic pain, such as trigeminal neuralgia, Lhermitte sign, and glossopharyngeal neuralgia. In addition to disease-modifying therapies of MS, multiple treatments are available to manage neuropathic pain secondary to MS, including medical, interventional, and surgical treatments with varying levels of evidence.

scholarly journals Blood serum amino acids profile in patients with Multiple Sclerosis

2015 ◽  
Vol 26 (1) ◽  
pp. 50-53
Keyword(s):  
Multiple Sclerosis ◽  
Amino Acids ◽  
Central Nervous System ◽  
Nervous System ◽  
Blood Serum ◽  
Demyelinating Disease ◽  
Initial Step ◽  
Control Group ◽  
The Central Nervous System ◽  
Amino Acids Profile

Multiple sclerosis is the most common demyelinating disease of the central nervous system, affecting mostly young people. There were many risk factors for MS identified, however a direct cause of the disease is still unknown. Pathological changes in the SM lead to the myelin sheath damage around axons, what prevents proper transmission of nerve impulses in the central nervous system. The aim of this study was analyzing and comparing the amino acids profile in the blood serum of MS patients to control group of healthy individuals and evaluating the relationship between them. Significant (p<0.05) differences in the level of glutamate, aspartate and taurine in the blood serum of MS patients were revealed. A positive glutamate and aspartate level correlation in the serum has been demonstrated. Gender is significant only in the case of glutamate level in blood serum. The studies highlight the important role of neurotransmitters in MS and are the initial step in proteomic research.

Movement Disorders

2016 ◽  
pp. 619-624
Author(s):  
Anhar Hassan ◽  
Eduardo E. Benarroch
Keyword(s):  
Multiple Sclerosis ◽  
Central Nervous System ◽  
Nervous System ◽  
Young Adults ◽  
Movement Disorders ◽  
Demyelinating Disease ◽  
Substantial Effect ◽  
The Central Nervous System

The most common inflammatory demyelinating disease of the central nervous system is multiple sclerosis, a disabling disorder that affects predominantly young adults between 20 and 50 years old. It affects women twice as often as men. Multiple sclerosis has a complex immunopathogenesis, variable prognosis, and an unpredictable course. Polygenic and environmental (possibly viral) factors probably have a substantial effect on susceptibility to multiple sclerosis.

Myricetin alleviates cuprizone-induced behavioral dysfunction and demyelination in mice by Nrf2 pathway

2016 ◽  
Vol 7 (10) ◽  
pp. 4332-4342 ◽  
Author(s):  
Qianying Zhang ◽  
Zhike Li ◽  
Shuangchan Wu ◽  
Xiaofei Li ◽  
Ying Sang ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Central Nervous System ◽  
Nervous System ◽  
Demyelinating Disease ◽  
Nrf2 Pathway ◽  
Behavioral Dysfunction ◽  
System P ◽  
The Central Nervous System

Multiple sclerosis (MS) is a demyelinating disease occurring in the central nervous system.

scholarly journals COMBINATION OF MULTIPLE SCLEROSIS AND HEREDITARY OPTICAL LEBER’S NEUROPATHY. CLINICAL CASE

2021 ◽  
Vol 30 (4) ◽  
pp. 50-54
Author(s):  
Azalia Aisarovna Sokolova ◽  
◽  
Leonid Sergeevich Zemlyanushin ◽  
Elvira Aysarovna Vashkulatova ◽  
Sofia Mikhailovna Zemlyanushina
Keyword(s):  
Multiple Sclerosis ◽  
Central Nervous System ◽  
Nervous System ◽  
Genetic Testing ◽  
Optic Nerve ◽  
Clinical Case ◽  
Demyelinating Disease ◽  
Mcdonald Criteria ◽  
The Central Nervous System ◽  
Hereditary Optic Atrophy

The article discusses a clinical case of demyelinating disease of the central nervous system, multiple sclerosis in combination with Leber’s hereditary optic atrophy of the optic nerve (Harding syndrome). The debut of the disease at the age of 24 in the form of a simultaneous bilateral decrease in vision, with subsequent atrophy of the optic nerves in both eyes. The diagnosis of multiple sclerosis was confi rmed according to the 2017 McDonald criteria, the diagnosis of Leber’s disease was confi rmed by genetic testing. An important point in the diff erential diagnosis was the identifi cation of the G3460A mutation in the ND1 gene and intrathecal synthesis of oligoclonal immunoglobulin G.

scholarly journals Syringomyelia in demyelinating disease of the central nervous system: Report of two cases

2011 ◽  
Vol 139 (9-10) ◽  
pp. 657-660 ◽  
Author(s):  
Dejan Savic ◽  
Slobodan Vojinovic ◽  
Mirjana Spasic ◽  
Zoran Peric ◽  
Stevo Lukic
Keyword(s):  
Multiple Sclerosis ◽  
Spinal Cord ◽  
Central Nervous System ◽  
Nervous System ◽  
Magnetic Resonance ◽  
Demyelinating Disease ◽  
Clinical Signs ◽  
Thoracic Spinal Cord ◽  
Thoracic Spinal ◽  
The Central Nervous System

Introduction. Syringomyelia is a cavitary extension inside the spinal cord which can be either symptomatic or congenitally-idiopathic. Syringomyelia during the course of the disease in patients presenting with clinically definite multiple sclerosis was described earlier. Syringomyelia in patients presenting with a clinically isolated syndrome suggestive of multiple sclerosis is unusual. Case Outline. We present two patients presenting with demy-elinating disease of the central nervous system with syringomyelia in the cervical and thoracic spinal cord. We did not find classical clinical signs of syringomyelia in our patients, but we disclosed syringomyelia incidentally during magnetic resonance exploration. Magnetic resonance exploration using the gadolinium contrast revealed the signs of active demyelinating lesions in the spinal cord in one patient but not in the other. Conclusion. Syringomyelia in demyelinating disease of the central nervous system opens the question whether it is a coincidental finding or a part of clinical features of the disease. Differentiation of the significance of syringomyelia finding in these patients plays a role in the choice of treatment concept in such patients.

scholarly journals Gender and Uveitis in Patients with Multiple Sclerosis

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Lynn K. Gordon ◽  
Debra A. Goldstein
Keyword(s):  
Multiple Sclerosis ◽  
Central Nervous System ◽  
Nervous System ◽  
Demyelinating Disease ◽  
Retinal Vasculitis ◽  
Signs And Symptoms ◽  
Intraocular Inflammation ◽  
Tnf Inhibitor ◽  
Intermediate Uveitis ◽  
The Central Nervous System

Multiple sclerosis (MS), a demyelinating disease of the central nervous system, is more commonly seen in women. It has been associated with both anterior and intermediate uveitis as well as retinal vasculitis. Ocular inflammation may develop concurrent with, prior to, or after the development of neurologic signs and symptoms. Patients with MS have an approximately 1% chance of developing intraocular inflammation. Patients with intermediate uveitis have an 8–12% risk of being diagnosed with MS. This risk is higher in females and in those with bilateral disease. This should be kept in mind when evaluating patients with uveitis, particularly in those patients for whom TNF inhibitor therapy is being considered, as these agents may worsen demyelinating disease.

scholarly journals Multiple Sclerosis Presenting with Facial Twitching (Myokymia and Hemifacial Spasms)

2017 ◽  
Vol 2017 ◽  
pp. 1-3 ◽  
Author(s):  
Risha Hertz ◽  
James Espinosa ◽  
Alan Lucerna ◽  
Doug Stranges
Keyword(s):  
Multiple Sclerosis ◽  
Spinal Cord ◽  
Central Nervous System ◽  
Cerebral Spinal Fluid ◽  
Demyelinating Disease ◽  
Signs And Symptoms ◽  
Current Medical ◽  
The Central Nervous System ◽  
Left Eyelid ◽  
Hemifacial Spasms

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system. The etiology is insufficiently understood. Autoimmune, genetic, viral, and environmental factors have been hypothesized. MS is twice as common in women as in men between the ages of 20 and 50 years. There is no known cure for MS. Current medical treatment helps to prevent new attacks and improve function after an attack. MS is diagnosed by physical examination, diagnostic imaging, and examination of cerebral spinal fluid. The most common physical signs and symptoms of MS include constitutional symptoms, muscle weakness, motor and autonomic spinal cord symptoms, paresthesias, and vision changes. Here we present a case of MS diagnosed in a 33-year-old male with facial myokymia of left eyelid, which progressed to left hemifacial spasm. This is an unusual presentation for multiple sclerosis. An awareness of this presentation not only may lead to an earlier diagnosis in some patients but can be a sign of relapse in patients with established multiple sclerosis.

scholarly journals The discovery of natalizumab, a potent therapeutic for multiple sclerosis

2012 ◽  
Vol 199 (3) ◽  
pp. 413-416 ◽  
Author(s):  
Lawrence Steinman
Keyword(s):  
Multiple Sclerosis ◽  
Central Nervous System ◽  
Immune Response ◽  
Nervous System ◽  
Immune Cells ◽  
Strong Evidence ◽  
Demyelinating Disease ◽  
Critical Component ◽  
The Central Nervous System ◽  
The Brain

Multiple sclerosis (MS) is the major inflammatory demyelinating disease of the central nervous system. There is strong evidence that an immune response in the brain is a critical component of the disease. In 1992, in a collaboration between academia and biotechnology, my colleagues and I showed that α4 integrin was the critical molecule involved in the homing of immune cells into the inflamed brain. Was it sheer luck that these results led to the development of a drug for MS?

scholarly journals Possible Correlation between Cholinergic System Alterations and Neuro/Inflammation in Multiple Sclerosis

Biomedicines ◽  
2020 ◽  
Vol 8 (6) ◽  
pp. 153
Author(s):  
Valentina Gatta ◽  
Guadalupe Mengod ◽  
Marcella Reale ◽  
Ada Maria Tata
Keyword(s):  
Multiple Sclerosis ◽  
Central Nervous System ◽  
Nervous System ◽  
Demyelinating Disease ◽  
Inflammatory Processes ◽  
The Central Nervous System ◽  
Neuro Inflammation ◽  
Hydrolyzing Enzymes ◽  
Genetic And Environmental Factors ◽  
Cholinergic Markers

Multiple sclerosis (MS) is an autoimmune and demyelinating disease of the central nervous system. Although the etiology of MS is still unknown, both genetic and environmental factors contribute to the pathogenesis of the disease. Acetylcholine participates in the modulation of central and peripheral inflammation. The cells of the immune system, as well as microglia, astrocytes and oligodendrocytes express cholinergic markers and receptors of muscarinic and nicotinic type. The role played by acetylcholine in MS has been recently investigated. In the present review, we summarize the evidence indicating the cholinergic dysfunction in serum and cerebrospinal fluid of relapsing–remitting (RR)-MS patients and in the brains of the MS animal model experimental autoimmune encephalomyelitis (EAE). The correlation between the increased activity of the cholinergic hydrolyzing enzymes acetylcholinesterase and butyrylcholinesterase, the reduced levels of acetylcholine and the increase of pro-inflammatory cytokines production were recently described in immune cells of MS patients. Moreover, the genetic polymorphisms for both hydrolyzing enzymes and the possible correlation with the altered levels of their enzymatic activity have been also reported. Finally, the changes in cholinergic markers expression in the central nervous system of EAE mice in peak and chronic phases suggest the involvement of the acetylcholine also in neuro-inflammatory processes.

Sign in / Sign up

Export Citation Format

Share Document